Neximmune Return on Equity

Neximmune (NEXI) currently reports a ROE of -336.76%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Neximmune's ROE history and peer comparisons.

Neximmune's ROE of -336.76% is lower than the Healthcare sector average of 21.28%. That is roughly 1682.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Neximmune's current -336.76% should be judged against Healthcare norms (sector average: 21.28%) and against NEXI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -336.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Neximmune, and consider following NEXI for alerts when major investors trade the stock.

Neximmune is classified in the Healthcare sector. On ROE, it currently shows -336.76% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NEXI with unrelated industries.